SAFE-HEaRt: A Pilot Study Assessing the Cardiac SAFEty of HER2 Targeted Therapy in Patients With HER2 Positive Breast Cancer and Reduced Left Ventricular Function

Trial Profile

SAFE-HEaRt: A Pilot Study Assessing the Cardiac SAFEty of HER2 Targeted Therapy in Patients With HER2 Positive Breast Cancer and Reduced Left Ventricular Function

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab emtansine (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Acronyms SAFE-HEaRt
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Feb 2015 Planned number of patients changed from 33 to 30, as reported by ClinicalTrials.gov.
    • 20 Aug 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top